Sofosbuvir and ledipasvir for HIV/HCV co-infected patients

Expert Opinion on Pharmacotherapy

Volumn 17, Issue 5, 2016, Pages 743-749

  Rosenthal, Elana S ^a   Kottilil, Shyam ^b   Polis, Michael A ^c  

^a FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

direct acting antivirals; Hepatitis C virus; HIV HCV co infection; ledipasvir sofosbuvir

Indexed keywords

ABACAVIR; AMIODARONE; ANTICONVULSIVE AGENT; ANTIMYCOBACTERIAL AGENT; ATAZANAVIR; DARUNAVIR; DOLUTEGRAVIR; EFAVIRENZ; EMTRICITABINE; ETRAVIRINE; HISTAMINE H2 RECEPTOR ANTAGONIST; LEDIPASVIR; NEVIRAPINE; PROTON PUMP INHIBITOR; RALTEGRAVIR; RILPIVIRINE; ROSUVASTATIN; SOFOSBUVIR; TENOFOVIR; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; FLUORENE DERIVATIVE;

ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; DIARRHEA; DRUG COST; DRUG EFFICACY; DRUG METABOLISM; DRUG TREATMENT FAILURE; FATIGUE; HEADACHE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSOMNIA; MIXED INFECTION; MULTICENTER STUDY (TOPIC); NAUSEA; NEPHROTOXICITY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); TREATMENT DURATION; COMBINATION DRUG THERAPY; COMPLICATION; DRUG INTERACTION; HEPATITIS C, CHRONIC; HIV INFECTIONS;

ANTIVIRAL AGENTS; BENZIMIDAZOLES; COINFECTION; DRUG INTERACTIONS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FLUORENES; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; SOFOSBUVIR;

EID: 84961212695     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2016.1157580     Document Type: Article

References (34)

1. Hepatitis C. 2015 [cited 2015 Aug 27]; Available from: http://www.who.int/mediacentre/factsheets/fs164/en/
2. CDC. HIV and Viral Hepatitis. March 2014 [cited 2015 Nov 5; Available from: http://www.cdc.gov/hepatitis/populations/pdfs/hivandhep-factsheet.pdf.
3. WHO. HIV and hepatitis coinfections. [cited 2015 Nov 20]; Available from: http://www.who.int/hiv/topics/hepatitis/hepatitisinfo/en/
4. Graham CS, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a metaanalysis. Clin Infect Dis. 2001;33(4):562-569.
5. Terrault NA, et al. Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection. Liver Transpl. 2012;18(6):716-726.
6. Afdhal N, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370(16):1483-93.
7. Afdhal N, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370(20):1889-98.
8. Kattakuzhy S, Levy R, Kottilil S. Sofosbuvir for treatment of chronic hepatitis C. Hepatol Int. 2015;9(2):161-173.
9. Harvoni [package insert]. Foster City, CA. Gilead Sciences; 2014. [cited 2015 10 1]; Available from: https://www.gilead.com/~/media/Files/pdfs/medicines/liver-disease/harvoni/harvoni-pi.pdf
10. Harvoni. In: Micromedex. Ann Arbor (MI): Truven Health Analytics. [cited 2015 Nov 15]
11. Fontaine H, et al. Bradyarrhythmias associated with sofosbuvir treatment. N Engl J Med. 2015;373(19):1886-1888.
12. Renet S, et al. Extreme bradycardia after first doses of sofosbuvir and daclatasvir in patients receiving amiodarone: 2 cases including a rechallenge. Gastroenterology. 2015;149(6):1378-1380 e1.
13. Terrault NA, Zeuzem S, Di Bisceglie AM, et al. (HCV-TARGET) - treatment outcomes with 8, 12 and 24 week regimens of ledipasvir/sofosbuvir for the treatment of hepatitis C infection: analysis of a multicenter prospective, observational study. AASLD 2015; 2015 Nov 13-17; San Francisco, CA.
14. Lontok E, et al. Hepatitis C virus drug resistance-associated substitutions: state of the art summary. Hepatology. 2015;62(5):1623-1632.
15. Kowdley KV, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370(20):1879-88.
16. Kattakuzhy S, et al. Moderate sustained virologic response rates with 6-week combination directly acting anti-hepatitis C virus therapy in patients with advanced liver disease. Clin Infect Dis. 2016;62(4):440-7.
17. Wilson EM, et al. Successful retreatment of chronic HCV genotype-1 infection with ledipasvir and sofosbuvir after initial short course therapy with direct-acting antiviral regimens. Clin Infect Dis. 2016;62(3):280-8.
18. Lawitz E. Retreatment of patientswho failed 8 or 12weeks of ledipasvir/sofosbuvir-based regimens with ledipasvir/sofosbuvir for 24 weeks. EASL-The International Liver Congress 2015; 2015 Apr 22-26; Vienna.
19. Osinusi A, et al. Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. Jama. 2015;313(12):1232-9.
20. Naggie S, et al. Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med. 2015;373(8):705-13.
21. El-Sherif O, Khoo S, Solas C. Key drug-drug interactions with directacting antiviral in HIV-HCV coinfection. Curr Opin HIV AIDS. 2015;10 (5):348-354.
22. German P. Pharmacokinetic analyses of ledipasvir/sofosbuvir and HIV antiretroviral regimens in subjects with HCV/HIV coinfection. AASLD 2015; 2015 Nov 13-17; San Francisco, CA.
23. AIDSinfo. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. 2015 [cited 2015 Nov 5]. Available from: https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adoles cent-arv-guidelines/26/hiv-hcv.
24. Ingiliz P, Sofosbuvir plus ledipasvir for 8 weeks in HCV-mono- and HIV-HCV-coinfected patients - results from the German Hepatitis C Cohort (GECCO). in 15th European AIDS Conference. Barcelona, October 21-24, 2015.
25. Osinusi A, Townsend K, Kottilil S. Drug-drug interactions in patients coinfected with HCV and HIV-reply. Jama. 2015;314(2):186-187.
26. Genvoya [package insert]. Foster City, CA: Gilead Sciences; 2015.
27. Sulkowski MS, et al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. Jama. 2015;313(12):1223-31.
28. Wyles DL, et al. Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med. 2015;373(8):714-25.
29. Rockstroh JK, et al. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV coinfection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. Lancet HIV. 2015;2(8):e319-27.
30. Trooskin SB, Reynolds H, Kostman JR. Access to costly new hepatitis C drugs: medicine, money, and advocacy. Clin Infect Dis. 2015;61 (12):1825-1830.
31. Barua S, et al. Restrictions for medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States. Ann Intern Med. 2015;163(3):215-223.
32. Lo Re V. Incidence and determinants of denial of DAA treatment for chronic HCV infection by insurance type during the first 6 months of the modern HCV treatment era. AASLD 2015; 2015 Nov 13-17; San Francisco, CA.
33. Silverman E. 2015 Feb 4. What the 'shocking' Gilead discounts on its hepatitis C drugs will mean. The Wall Street Journal [Internet]. [cited 2015 Oct 19]. Available from: http://blogs.wsj.com/pharma lot/2015/02/04/what-the-shocking-gilead-discounts-on-its-hepati tis-c-drugs-will-mean/
34. Graham CS, Swan T. A path to eradication of hepatitis C in low- and middle-income countries. Antiviral Res. 2015;119:89-96.